nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—PPP3CA—prostate cancer	0.311	0.774	CbGaD
Tacrolimus—CYP3A5—prostate cancer	0.0636	0.158	CbGaD
Tacrolimus—ORM1—Abiraterone—prostate cancer	0.0502	0.154	CbGbCtD
Tacrolimus—CYP3A4—prostate cancer	0.0275	0.0684	CbGaD
Tacrolimus—ALB—Abiraterone—prostate cancer	0.0211	0.0648	CbGbCtD
Tacrolimus—CYP3A5—Flutamide—prostate cancer	0.017	0.0521	CbGbCtD
Tacrolimus—ALB—Estrone—prostate cancer	0.0153	0.0468	CbGbCtD
Tacrolimus—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0152	0.0466	CbGbCtD
Tacrolimus—CYP3A5—Cabazitaxel—prostate cancer	0.0125	0.0385	CbGbCtD
Tacrolimus—ABCB1—Estramustine—prostate cancer	0.0124	0.038	CbGbCtD
Tacrolimus—CYP3A5—Estrone—prostate cancer	0.0123	0.0376	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.00939	0.0288	CbGbCtD
Tacrolimus—CYP3A7—Estradiol—prostate cancer	0.00939	0.0288	CbGbCtD
Tacrolimus—ALB—Estradiol—prostate cancer	0.00876	0.0269	CbGbCtD
Tacrolimus—ABCB1—Cabazitaxel—prostate cancer	0.00816	0.0251	CbGbCtD
Tacrolimus—CYP3A4—Bicalutamide—prostate cancer	0.00798	0.0245	CbGbCtD
Tacrolimus—ABCB1—Estrone—prostate cancer	0.00798	0.0245	CbGbCtD
Tacrolimus—ALB—Prednisone—prostate cancer	0.00753	0.0231	CbGbCtD
Tacrolimus—CYP3A4—Estramustine—prostate cancer	0.00742	0.0228	CbGbCtD
Tacrolimus—ABCB1—Ethinyl Estradiol—prostate cancer	0.00711	0.0218	CbGbCtD
Tacrolimus—CYP3A5—Estradiol—prostate cancer	0.00704	0.0216	CbGbCtD
Tacrolimus—CYP3A4—Flutamide—prostate cancer	0.00661	0.0203	CbGbCtD
Tacrolimus—CYP3A4—Abiraterone—prostate cancer	0.00661	0.0203	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.00561	0.0172	CbGbCtD
Tacrolimus—CYP3A7—Docetaxel—prostate cancer	0.00561	0.0172	CbGbCtD
Tacrolimus—ABCB1—Conjugated Estrogens—prostate cancer	0.00522	0.016	CbGbCtD
Tacrolimus—CYP3A4—Cabazitaxel—prostate cancer	0.00489	0.015	CbGbCtD
Tacrolimus—CYP3A4—Estrone—prostate cancer	0.00478	0.0147	CbGbCtD
Tacrolimus—ABCB1—Mitoxantrone—prostate cancer	0.00475	0.0146	CbGbCtD
Tacrolimus—CYP3A5—Etoposide—prostate cancer	0.0046	0.0141	CbGbCtD
Tacrolimus—ABCB1—Estradiol—prostate cancer	0.00458	0.0141	CbGbCtD
Tacrolimus—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00426	0.0131	CbGbCtD
Tacrolimus—CYP3A5—Docetaxel—prostate cancer	0.00421	0.0129	CbGbCtD
Tacrolimus—ABCB1—Prednisone—prostate cancer	0.00394	0.0121	CbGbCtD
Tacrolimus—CYP3A4—Conjugated Estrogens—prostate cancer	0.00313	0.0096	CbGbCtD
Tacrolimus—ABCB1—Etoposide—prostate cancer	0.00299	0.00919	CbGbCtD
Tacrolimus—CYP3A4—Mitoxantrone—prostate cancer	0.00284	0.00873	CbGbCtD
Tacrolimus—CYP3A4—Estradiol—prostate cancer	0.00275	0.00843	CbGbCtD
Tacrolimus—ABCB1—Docetaxel—prostate cancer	0.00274	0.00841	CbGbCtD
Tacrolimus—ABCA5—prostate gland—prostate cancer	0.00258	0.0732	CbGeAlD
Tacrolimus—CYP3A4—Prednisone—prostate cancer	0.00236	0.00725	CbGbCtD
Tacrolimus—ABCA5—seminal vesicle—prostate cancer	0.00218	0.0619	CbGeAlD
Tacrolimus—ABCB1—Doxorubicin—prostate cancer	0.00204	0.00627	CbGbCtD
Tacrolimus—CYP3A4—Etoposide—prostate cancer	0.00179	0.0055	CbGbCtD
Tacrolimus—PPP3CA—prostate gland—prostate cancer	0.00174	0.0494	CbGeAlD
Tacrolimus—ABCA5—urethra—prostate cancer	0.00173	0.049	CbGeAlD
Tacrolimus—CYP3A4—Docetaxel—prostate cancer	0.00164	0.00504	CbGbCtD
Tacrolimus—PPP3CA—seminal vesicle—prostate cancer	0.00147	0.0418	CbGeAlD
Tacrolimus—ABCA5—bone marrow—prostate cancer	0.00133	0.0377	CbGeAlD
Tacrolimus—MTOR—prostate gland—prostate cancer	0.00129	0.0365	CbGeAlD
Tacrolimus—CYP3A4—Doxorubicin—prostate cancer	0.00122	0.00375	CbGbCtD
Tacrolimus—PPP3CA—renal system—prostate cancer	0.00119	0.0337	CbGeAlD
Tacrolimus—PPP3CA—urethra—prostate cancer	0.00117	0.0331	CbGeAlD
Tacrolimus—FKBP1A—prostate gland—prostate cancer	0.00116	0.0328	CbGeAlD
Tacrolimus—ABCA5—testis—prostate cancer	0.00114	0.0322	CbGeAlD
Tacrolimus—MTOR—seminal vesicle—prostate cancer	0.00109	0.0309	CbGeAlD
Tacrolimus—CYP3A4—urine—prostate cancer	0.00105	0.0299	CbGeAlD
Tacrolimus—FKBP1A—seminal vesicle—prostate cancer	0.00098	0.0278	CbGeAlD
Tacrolimus—MTOR—epithelium—prostate cancer	0.000947	0.0268	CbGeAlD
Tacrolimus—ORM1—prostate gland—prostate cancer	0.000907	0.0257	CbGeAlD
Tacrolimus—PPP3CA—bone marrow—prostate cancer	0.000899	0.0255	CbGeAlD
Tacrolimus—MTOR—renal system—prostate cancer	0.000878	0.0249	CbGeAlD
Tacrolimus—FKBP1A—epithelium—prostate cancer	0.000851	0.0241	CbGeAlD
Tacrolimus—Sirolimus—FGF2—prostate cancer	0.000849	0.363	CrCbGaD
Tacrolimus—ABCA5—lymph node—prostate cancer	0.000824	0.0234	CbGeAlD
Tacrolimus—FKBP1A—renal system—prostate cancer	0.00079	0.0224	CbGeAlD
Tacrolimus—FKBP1A—urethra—prostate cancer	0.000776	0.022	CbGeAlD
Tacrolimus—PPP3CA—testis—prostate cancer	0.000768	0.0218	CbGeAlD
Tacrolimus—MTOR—bone marrow—prostate cancer	0.000664	0.0188	CbGeAlD
Tacrolimus—FKBP1A—bone marrow—prostate cancer	0.000597	0.0169	CbGeAlD
Tacrolimus—MTOR—testis—prostate cancer	0.000567	0.0161	CbGeAlD
Tacrolimus—PPP3CA—lymph node—prostate cancer	0.000557	0.0158	CbGeAlD
Tacrolimus—FKBP1A—testis—prostate cancer	0.00051	0.0145	CbGeAlD
Tacrolimus—CYP3A5—prostate gland—prostate cancer	0.000505	0.0143	CbGeAlD
Tacrolimus—ORM1—bone marrow—prostate cancer	0.000467	0.0132	CbGeAlD
Tacrolimus—MTOR—lymph node—prostate cancer	0.000411	0.0117	CbGeAlD
Tacrolimus—Temsirolimus—CYP3A5—prostate cancer	0.000375	0.16	CrCbGaD
Tacrolimus—FKBP1A—lymph node—prostate cancer	0.00037	0.0105	CbGeAlD
Tacrolimus—ALB—testis—prostate cancer	0.00035	0.00993	CbGeAlD
Tacrolimus—CYP3A5—renal system—prostate cancer	0.000344	0.00974	CbGeAlD
Tacrolimus—Sirolimus—CYP3A5—prostate cancer	0.00033	0.141	CrCbGaD
Tacrolimus—ORM1—lymph node—prostate cancer	0.00029	0.00821	CbGeAlD
Tacrolimus—ABCB1—prostate gland—prostate cancer	0.000268	0.00759	CbGeAlD
Tacrolimus—CYP3A4—renal system—prostate cancer	0.000258	0.00731	CbGeAlD
Tacrolimus—ALB—lymph node—prostate cancer	0.000254	0.0072	CbGeAlD
Tacrolimus—Everolimus—CYP3A4—prostate cancer	0.00024	0.103	CrCbGaD
Tacrolimus—Pimecrolimus—CYP3A4—prostate cancer	0.00024	0.103	CrCbGaD
Tacrolimus—ABCB1—seminal vesicle—prostate cancer	0.000227	0.00642	CbGeAlD
Tacrolimus—ABCB1—epithelium—prostate cancer	0.000197	0.00558	CbGeAlD
Tacrolimus—ABCB1—renal system—prostate cancer	0.000183	0.00518	CbGeAlD
Tacrolimus—ABCB1—urethra—prostate cancer	0.000179	0.00509	CbGeAlD
Tacrolimus—Temsirolimus—CYP3A4—prostate cancer	0.000162	0.0694	CrCbGaD
Tacrolimus—Sirolimus—CYP3A4—prostate cancer	0.000143	0.0611	CrCbGaD
Tacrolimus—ABCB1—bone marrow—prostate cancer	0.000138	0.00391	CbGeAlD
Tacrolimus—ABCB1—testis—prostate cancer	0.000118	0.00335	CbGeAlD
Tacrolimus—ABCB1—lymph node—prostate cancer	8.56e-05	0.00243	CbGeAlD
Tacrolimus—Haemoglobin—Doxorubicin—prostate cancer	1.31e-05	8.96e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Capecitabine—prostate cancer	1.31e-05	8.95e-05	CcSEcCtD
Tacrolimus—Flushing—Epirubicin—prostate cancer	1.31e-05	8.94e-05	CcSEcCtD
Tacrolimus—Cardiac disorder—Epirubicin—prostate cancer	1.31e-05	8.94e-05	CcSEcCtD
Tacrolimus—Rhinitis—Doxorubicin—prostate cancer	1.31e-05	8.94e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Docetaxel—prostate cancer	1.31e-05	8.93e-05	CcSEcCtD
Tacrolimus—Haemorrhage—Doxorubicin—prostate cancer	1.3e-05	8.91e-05	CcSEcCtD
Tacrolimus—Hepatitis—Doxorubicin—prostate cancer	1.3e-05	8.91e-05	CcSEcCtD
Tacrolimus—Insomnia—Capecitabine—prostate cancer	1.3e-05	8.89e-05	CcSEcCtD
Tacrolimus—Hypoaesthesia—Doxorubicin—prostate cancer	1.3e-05	8.87e-05	CcSEcCtD
Tacrolimus—Pharyngitis—Doxorubicin—prostate cancer	1.29e-05	8.85e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Capecitabine—prostate cancer	1.29e-05	8.82e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Docetaxel—prostate cancer	1.29e-05	8.82e-05	CcSEcCtD
Tacrolimus—Urinary tract disorder—Doxorubicin—prostate cancer	1.29e-05	8.8e-05	CcSEcCtD
Tacrolimus—Oedema peripheral—Doxorubicin—prostate cancer	1.29e-05	8.78e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Docetaxel—prostate cancer	1.28e-05	8.76e-05	CcSEcCtD
Tacrolimus—Asthenia—Etoposide—prostate cancer	1.28e-05	8.76e-05	CcSEcCtD
Tacrolimus—Connective tissue disorder—Doxorubicin—prostate cancer	1.28e-05	8.76e-05	CcSEcCtD
Tacrolimus—Dyspnoea—Capecitabine—prostate cancer	1.28e-05	8.76e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Prednisone—prostate cancer	1.28e-05	8.75e-05	CcSEcCtD
Tacrolimus—Oedema—Prednisone—prostate cancer	1.28e-05	8.75e-05	CcSEcCtD
Tacrolimus—Fatigue—Docetaxel—prostate cancer	1.28e-05	8.75e-05	CcSEcCtD
Tacrolimus—Angiopathy—Epirubicin—prostate cancer	1.28e-05	8.74e-05	CcSEcCtD
Tacrolimus—Urethral disorder—Doxorubicin—prostate cancer	1.28e-05	8.74e-05	CcSEcCtD
Tacrolimus—Nausea—Mitoxantrone—prostate cancer	1.28e-05	8.72e-05	CcSEcCtD
Tacrolimus—Immune system disorder—Epirubicin—prostate cancer	1.27e-05	8.7e-05	CcSEcCtD
Tacrolimus—Infection—Prednisone—prostate cancer	1.27e-05	8.7e-05	CcSEcCtD
Tacrolimus—Mediastinal disorder—Epirubicin—prostate cancer	1.27e-05	8.68e-05	CcSEcCtD
Tacrolimus—Pain—Docetaxel—prostate cancer	1.27e-05	8.68e-05	CcSEcCtD
Tacrolimus—Constipation—Docetaxel—prostate cancer	1.27e-05	8.68e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Capecitabine—prostate cancer	1.27e-05	8.65e-05	CcSEcCtD
Tacrolimus—Chills—Epirubicin—prostate cancer	1.27e-05	8.65e-05	CcSEcCtD
Tacrolimus—Pruritus—Etoposide—prostate cancer	1.26e-05	8.64e-05	CcSEcCtD
Tacrolimus—Shock—Prednisone—prostate cancer	1.26e-05	8.61e-05	CcSEcCtD
Tacrolimus—Arrhythmia—Epirubicin—prostate cancer	1.26e-05	8.61e-05	CcSEcCtD
Tacrolimus—Visual impairment—Doxorubicin—prostate cancer	1.26e-05	8.59e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Prednisone—prostate cancer	1.26e-05	8.58e-05	CcSEcCtD
Tacrolimus—Tachycardia—Prednisone—prostate cancer	1.25e-05	8.54e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Capecitabine—prostate cancer	1.25e-05	8.54e-05	CcSEcCtD
Tacrolimus—Alopecia—Epirubicin—prostate cancer	1.25e-05	8.51e-05	CcSEcCtD
Tacrolimus—Skin disorder—Prednisone—prostate cancer	1.24e-05	8.5e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Capecitabine—prostate cancer	1.24e-05	8.48e-05	CcSEcCtD
Tacrolimus—Fatigue—Capecitabine—prostate cancer	1.24e-05	8.47e-05	CcSEcCtD
Tacrolimus—Hyperhidrosis—Prednisone—prostate cancer	1.24e-05	8.46e-05	CcSEcCtD
Tacrolimus—Mental disorder—Epirubicin—prostate cancer	1.24e-05	8.44e-05	CcSEcCtD
Tacrolimus—Erythema multiforme—Doxorubicin—prostate cancer	1.23e-05	8.43e-05	CcSEcCtD
Tacrolimus—Pain—Capecitabine—prostate cancer	1.23e-05	8.4e-05	CcSEcCtD
Tacrolimus—Constipation—Capecitabine—prostate cancer	1.23e-05	8.4e-05	CcSEcCtD
Tacrolimus—Erythema—Epirubicin—prostate cancer	1.23e-05	8.39e-05	CcSEcCtD
Tacrolimus—Malnutrition—Epirubicin—prostate cancer	1.23e-05	8.39e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Docetaxel—prostate cancer	1.22e-05	8.36e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Etoposide—prostate cancer	1.22e-05	8.36e-05	CcSEcCtD
Tacrolimus—Anorexia—Prednisone—prostate cancer	1.22e-05	8.34e-05	CcSEcCtD
Tacrolimus—Eye disorder—Doxorubicin—prostate cancer	1.22e-05	8.33e-05	CcSEcCtD
Tacrolimus—Tinnitus—Doxorubicin—prostate cancer	1.22e-05	8.31e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Docetaxel—prostate cancer	1.21e-05	8.3e-05	CcSEcCtD
Tacrolimus—Flushing—Doxorubicin—prostate cancer	1.21e-05	8.27e-05	CcSEcCtD
Tacrolimus—Cardiac disorder—Doxorubicin—prostate cancer	1.21e-05	8.27e-05	CcSEcCtD
Tacrolimus—Flatulence—Epirubicin—prostate cancer	1.21e-05	8.26e-05	CcSEcCtD
Tacrolimus—Tension—Epirubicin—prostate cancer	1.2e-05	8.23e-05	CcSEcCtD
Tacrolimus—Dysgeusia—Epirubicin—prostate cancer	1.2e-05	8.21e-05	CcSEcCtD
Tacrolimus—Nervousness—Epirubicin—prostate cancer	1.19e-05	8.15e-05	CcSEcCtD
Tacrolimus—Back pain—Epirubicin—prostate cancer	1.19e-05	8.11e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Capecitabine—prostate cancer	1.18e-05	8.1e-05	CcSEcCtD
Tacrolimus—Angiopathy—Doxorubicin—prostate cancer	1.18e-05	8.09e-05	CcSEcCtD
Tacrolimus—Dizziness—Etoposide—prostate cancer	1.18e-05	8.08e-05	CcSEcCtD
Tacrolimus—Muscle spasms—Epirubicin—prostate cancer	1.18e-05	8.06e-05	CcSEcCtD
Tacrolimus—Immune system disorder—Doxorubicin—prostate cancer	1.18e-05	8.05e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Capecitabine—prostate cancer	1.18e-05	8.03e-05	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—prostate cancer	1.18e-05	8.03e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Docetaxel—prostate cancer	1.17e-05	8.02e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Docetaxel—prostate cancer	1.17e-05	8.02e-05	CcSEcCtD
Tacrolimus—Chills—Doxorubicin—prostate cancer	1.17e-05	8e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Prednisone—prostate cancer	1.17e-05	7.97e-05	CcSEcCtD
Tacrolimus—Arrhythmia—Doxorubicin—prostate cancer	1.17e-05	7.96e-05	CcSEcCtD
Tacrolimus—Insomnia—Prednisone—prostate cancer	1.16e-05	7.92e-05	CcSEcCtD
Tacrolimus—Vision blurred—Epirubicin—prostate cancer	1.16e-05	7.9e-05	CcSEcCtD
Tacrolimus—Alopecia—Doxorubicin—prostate cancer	1.15e-05	7.88e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Prednisone—prostate cancer	1.15e-05	7.86e-05	CcSEcCtD
Tacrolimus—Mental disorder—Doxorubicin—prostate cancer	1.14e-05	7.81e-05	CcSEcCtD
Tacrolimus—Urticaria—Capecitabine—prostate cancer	1.14e-05	7.81e-05	CcSEcCtD
Tacrolimus—Ill-defined disorder—Epirubicin—prostate cancer	1.14e-05	7.78e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Capecitabine—prostate cancer	1.14e-05	7.77e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Capecitabine—prostate cancer	1.14e-05	7.77e-05	CcSEcCtD
Tacrolimus—Vomiting—Etoposide—prostate cancer	1.14e-05	7.76e-05	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—prostate cancer	1.14e-05	7.76e-05	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—prostate cancer	1.14e-05	7.76e-05	CcSEcCtD
Tacrolimus—Anaemia—Epirubicin—prostate cancer	1.13e-05	7.75e-05	CcSEcCtD
Tacrolimus—Agitation—Epirubicin—prostate cancer	1.13e-05	7.71e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Prednisone—prostate cancer	1.13e-05	7.7e-05	CcSEcCtD
Tacrolimus—Rash—Etoposide—prostate cancer	1.13e-05	7.7e-05	CcSEcCtD
Tacrolimus—Dermatitis—Etoposide—prostate cancer	1.13e-05	7.69e-05	CcSEcCtD
Tacrolimus—Headache—Etoposide—prostate cancer	1.12e-05	7.65e-05	CcSEcCtD
Tacrolimus—Flatulence—Doxorubicin—prostate cancer	1.12e-05	7.65e-05	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—prostate cancer	1.11e-05	7.62e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Prednisone—prostate cancer	1.11e-05	7.61e-05	CcSEcCtD
Tacrolimus—Dysgeusia—Doxorubicin—prostate cancer	1.11e-05	7.6e-05	CcSEcCtD
Tacrolimus—Malaise—Epirubicin—prostate cancer	1.11e-05	7.56e-05	CcSEcCtD
Tacrolimus—Fatigue—Prednisone—prostate cancer	1.1e-05	7.55e-05	CcSEcCtD
Tacrolimus—Nervousness—Doxorubicin—prostate cancer	1.1e-05	7.54e-05	CcSEcCtD
Tacrolimus—Vertigo—Epirubicin—prostate cancer	1.1e-05	7.54e-05	CcSEcCtD
Tacrolimus—Syncope—Epirubicin—prostate cancer	1.1e-05	7.52e-05	CcSEcCtD
Tacrolimus—Leukopenia—Epirubicin—prostate cancer	1.1e-05	7.51e-05	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—prostate cancer	1.1e-05	7.51e-05	CcSEcCtD
Tacrolimus—Constipation—Prednisone—prostate cancer	1.1e-05	7.48e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Docetaxel—prostate cancer	1.09e-05	7.48e-05	CcSEcCtD
Tacrolimus—Muscle spasms—Doxorubicin—prostate cancer	1.09e-05	7.46e-05	CcSEcCtD
Tacrolimus—Palpitations—Epirubicin—prostate cancer	1.08e-05	7.41e-05	CcSEcCtD
Tacrolimus—Loss of consciousness—Epirubicin—prostate cancer	1.08e-05	7.37e-05	CcSEcCtD
Tacrolimus—Cough—Epirubicin—prostate cancer	1.07e-05	7.32e-05	CcSEcCtD
Tacrolimus—Vision blurred—Doxorubicin—prostate cancer	1.07e-05	7.31e-05	CcSEcCtD
Tacrolimus—Asthenia—Docetaxel—prostate cancer	1.07e-05	7.28e-05	CcSEcCtD
Tacrolimus—Convulsion—Epirubicin—prostate cancer	1.06e-05	7.27e-05	CcSEcCtD
Tacrolimus—Nausea—Etoposide—prostate cancer	1.06e-05	7.25e-05	CcSEcCtD
Tacrolimus—Hypertension—Epirubicin—prostate cancer	1.06e-05	7.24e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Capecitabine—prostate cancer	1.06e-05	7.24e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Prednisone—prostate cancer	1.06e-05	7.21e-05	CcSEcCtD
Tacrolimus—Ill-defined disorder—Doxorubicin—prostate cancer	1.05e-05	7.2e-05	CcSEcCtD
Tacrolimus—Pruritus—Docetaxel—prostate cancer	1.05e-05	7.18e-05	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—prostate cancer	1.05e-05	7.17e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Prednisone—prostate cancer	1.05e-05	7.16e-05	CcSEcCtD
Tacrolimus—Arthralgia—Epirubicin—prostate cancer	1.04e-05	7.14e-05	CcSEcCtD
Tacrolimus—Chest pain—Epirubicin—prostate cancer	1.04e-05	7.14e-05	CcSEcCtD
Tacrolimus—Myalgia—Epirubicin—prostate cancer	1.04e-05	7.14e-05	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—prostate cancer	1.04e-05	7.13e-05	CcSEcCtD
Tacrolimus—Anxiety—Epirubicin—prostate cancer	1.04e-05	7.12e-05	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.04e-05	7.09e-05	CcSEcCtD
Tacrolimus—Discomfort—Epirubicin—prostate cancer	1.03e-05	7.06e-05	CcSEcCtD
Tacrolimus—Asthenia—Capecitabine—prostate cancer	1.03e-05	7.05e-05	CcSEcCtD
Tacrolimus—Malaise—Doxorubicin—prostate cancer	1.02e-05	7e-05	CcSEcCtD
Tacrolimus—Dry mouth—Epirubicin—prostate cancer	1.02e-05	6.98e-05	CcSEcCtD
Tacrolimus—Vertigo—Doxorubicin—prostate cancer	1.02e-05	6.97e-05	CcSEcCtD
Tacrolimus—Syncope—Doxorubicin—prostate cancer	1.02e-05	6.96e-05	CcSEcCtD
Tacrolimus—Urticaria—Prednisone—prostate cancer	1.02e-05	6.95e-05	CcSEcCtD
Tacrolimus—Pruritus—Capecitabine—prostate cancer	1.02e-05	6.95e-05	CcSEcCtD
Tacrolimus—Leukopenia—Doxorubicin—prostate cancer	1.02e-05	6.95e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Docetaxel—prostate cancer	1.02e-05	6.94e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Prednisone—prostate cancer	1.01e-05	6.92e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Prednisone—prostate cancer	1.01e-05	6.92e-05	CcSEcCtD
Tacrolimus—Confusional state—Epirubicin—prostate cancer	1.01e-05	6.9e-05	CcSEcCtD
Tacrolimus—Palpitations—Doxorubicin—prostate cancer	1e-05	6.86e-05	CcSEcCtD
Tacrolimus—Oedema—Epirubicin—prostate cancer	1e-05	6.85e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Epirubicin—prostate cancer	1e-05	6.85e-05	CcSEcCtD
Tacrolimus—Loss of consciousness—Doxorubicin—prostate cancer	9.98e-06	6.82e-05	CcSEcCtD
Tacrolimus—Infection—Epirubicin—prostate cancer	9.95e-06	6.8e-05	CcSEcCtD
Tacrolimus—Cough—Doxorubicin—prostate cancer	9.91e-06	6.77e-05	CcSEcCtD
Tacrolimus—Shock—Epirubicin—prostate cancer	9.86e-06	6.73e-05	CcSEcCtD
Tacrolimus—Convulsion—Doxorubicin—prostate cancer	9.84e-06	6.72e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Capecitabine—prostate cancer	9.84e-06	6.72e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Epirubicin—prostate cancer	9.82e-06	6.71e-05	CcSEcCtD
Tacrolimus—Dizziness—Docetaxel—prostate cancer	9.82e-06	6.71e-05	CcSEcCtD
Tacrolimus—Thrombocytopenia—Epirubicin—prostate cancer	9.81e-06	6.7e-05	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—prostate cancer	9.81e-06	6.7e-05	CcSEcCtD
Tacrolimus—Tachycardia—Epirubicin—prostate cancer	9.78e-06	6.68e-05	CcSEcCtD
Tacrolimus—Skin disorder—Epirubicin—prostate cancer	9.73e-06	6.65e-05	CcSEcCtD
Tacrolimus—Hyperhidrosis—Epirubicin—prostate cancer	9.68e-06	6.62e-05	CcSEcCtD
Tacrolimus—Chest pain—Doxorubicin—prostate cancer	9.67e-06	6.61e-05	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—prostate cancer	9.67e-06	6.61e-05	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—prostate cancer	9.67e-06	6.61e-05	CcSEcCtD
Tacrolimus—Anxiety—Doxorubicin—prostate cancer	9.64e-06	6.58e-05	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	9.6e-06	6.56e-05	CcSEcCtD
Tacrolimus—Discomfort—Doxorubicin—prostate cancer	9.55e-06	6.53e-05	CcSEcCtD
Tacrolimus—Anorexia—Epirubicin—prostate cancer	9.55e-06	6.52e-05	CcSEcCtD
Tacrolimus—Dizziness—Capecitabine—prostate cancer	9.51e-06	6.5e-05	CcSEcCtD
Tacrolimus—Dry mouth—Doxorubicin—prostate cancer	9.46e-06	6.46e-05	CcSEcCtD
Tacrolimus—Vomiting—Docetaxel—prostate cancer	9.44e-06	6.45e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Prednisone—prostate cancer	9.44e-06	6.45e-05	CcSEcCtD
Tacrolimus—Rash—Docetaxel—prostate cancer	9.36e-06	6.4e-05	CcSEcCtD
Tacrolimus—Hypotension—Epirubicin—prostate cancer	9.36e-06	6.4e-05	CcSEcCtD
Tacrolimus—Dermatitis—Docetaxel—prostate cancer	9.36e-06	6.39e-05	CcSEcCtD
Tacrolimus—Confusional state—Doxorubicin—prostate cancer	9.35e-06	6.39e-05	CcSEcCtD
Tacrolimus—Headache—Docetaxel—prostate cancer	9.3e-06	6.36e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—prostate cancer	9.27e-06	6.33e-05	CcSEcCtD
Tacrolimus—Oedema—Doxorubicin—prostate cancer	9.27e-06	6.33e-05	CcSEcCtD
Tacrolimus—Infection—Doxorubicin—prostate cancer	9.21e-06	6.29e-05	CcSEcCtD
Tacrolimus—Asthenia—Prednisone—prostate cancer	9.19e-06	6.28e-05	CcSEcCtD
Tacrolimus—Vomiting—Capecitabine—prostate cancer	9.14e-06	6.25e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Epirubicin—prostate cancer	9.13e-06	6.24e-05	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—prostate cancer	9.12e-06	6.23e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Doxorubicin—prostate cancer	9.09e-06	6.21e-05	CcSEcCtD
Tacrolimus—Thrombocytopenia—Doxorubicin—prostate cancer	9.08e-06	6.2e-05	CcSEcCtD
Tacrolimus—Rash—Capecitabine—prostate cancer	9.07e-06	6.2e-05	CcSEcCtD
Tacrolimus—Pruritus—Prednisone—prostate cancer	9.06e-06	6.19e-05	CcSEcCtD
Tacrolimus—Insomnia—Epirubicin—prostate cancer	9.06e-06	6.19e-05	CcSEcCtD
Tacrolimus—Dermatitis—Capecitabine—prostate cancer	9.06e-06	6.19e-05	CcSEcCtD
Tacrolimus—Tachycardia—Doxorubicin—prostate cancer	9.05e-06	6.18e-05	CcSEcCtD
Tacrolimus—Headache—Capecitabine—prostate cancer	9.01e-06	6.16e-05	CcSEcCtD
Tacrolimus—Skin disorder—Doxorubicin—prostate cancer	9e-06	6.15e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Epirubicin—prostate cancer	9e-06	6.15e-05	CcSEcCtD
Tacrolimus—Hyperhidrosis—Doxorubicin—prostate cancer	8.96e-06	6.12e-05	CcSEcCtD
Tacrolimus—Dyspnoea—Epirubicin—prostate cancer	8.93e-06	6.1e-05	CcSEcCtD
Tacrolimus—Somnolence—Epirubicin—prostate cancer	8.91e-06	6.09e-05	CcSEcCtD
Tacrolimus—Anorexia—Doxorubicin—prostate cancer	8.84e-06	6.04e-05	CcSEcCtD
Tacrolimus—Nausea—Docetaxel—prostate cancer	8.82e-06	6.03e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Epirubicin—prostate cancer	8.82e-06	6.03e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Prednisone—prostate cancer	8.76e-06	5.99e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Epirubicin—prostate cancer	8.71e-06	5.95e-05	CcSEcCtD
Tacrolimus—Hypotension—Doxorubicin—prostate cancer	8.66e-06	5.92e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Epirubicin—prostate cancer	8.65e-06	5.91e-05	CcSEcCtD
Tacrolimus—Fatigue—Epirubicin—prostate cancer	8.64e-06	5.9e-05	CcSEcCtD
Tacrolimus—Pain—Epirubicin—prostate cancer	8.57e-06	5.85e-05	CcSEcCtD
Tacrolimus—Constipation—Epirubicin—prostate cancer	8.57e-06	5.85e-05	CcSEcCtD
Tacrolimus—Nausea—Capecitabine—prostate cancer	8.54e-06	5.84e-05	CcSEcCtD
Tacrolimus—Dizziness—Prednisone—prostate cancer	8.47e-06	5.79e-05	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—prostate cancer	8.44e-06	5.77e-05	CcSEcCtD
Tacrolimus—Insomnia—Doxorubicin—prostate cancer	8.38e-06	5.73e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Doxorubicin—prostate cancer	8.32e-06	5.69e-05	CcSEcCtD
Tacrolimus—Dyspnoea—Doxorubicin—prostate cancer	8.26e-06	5.65e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Epirubicin—prostate cancer	8.25e-06	5.64e-05	CcSEcCtD
Tacrolimus—Somnolence—Doxorubicin—prostate cancer	8.24e-06	5.63e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Epirubicin—prostate cancer	8.19e-06	5.6e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Doxorubicin—prostate cancer	8.16e-06	5.58e-05	CcSEcCtD
Tacrolimus—Vomiting—Prednisone—prostate cancer	8.14e-06	5.56e-05	CcSEcCtD
Tacrolimus—Rash—Prednisone—prostate cancer	8.08e-06	5.52e-05	CcSEcCtD
Tacrolimus—Dermatitis—Prednisone—prostate cancer	8.07e-06	5.51e-05	CcSEcCtD
Tacrolimus—Decreased appetite—Doxorubicin—prostate cancer	8.06e-06	5.51e-05	CcSEcCtD
Tacrolimus—Headache—Prednisone—prostate cancer	8.02e-06	5.48e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—prostate cancer	8e-06	5.47e-05	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—prostate cancer	7.99e-06	5.46e-05	CcSEcCtD
Tacrolimus—Urticaria—Epirubicin—prostate cancer	7.96e-06	5.44e-05	CcSEcCtD
Tacrolimus—Pain—Doxorubicin—prostate cancer	7.93e-06	5.42e-05	CcSEcCtD
Tacrolimus—Constipation—Doxorubicin—prostate cancer	7.93e-06	5.42e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Epirubicin—prostate cancer	7.92e-06	5.41e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Epirubicin—prostate cancer	7.92e-06	5.41e-05	CcSEcCtD
Tacrolimus—Feeling abnormal—Doxorubicin—prostate cancer	7.64e-06	5.22e-05	CcSEcCtD
Tacrolimus—Nausea—Prednisone—prostate cancer	7.61e-06	5.2e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Doxorubicin—prostate cancer	7.58e-06	5.18e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Epirubicin—prostate cancer	7.38e-06	5.04e-05	CcSEcCtD
Tacrolimus—Urticaria—Doxorubicin—prostate cancer	7.36e-06	5.03e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Doxorubicin—prostate cancer	7.33e-06	5.01e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Doxorubicin—prostate cancer	7.33e-06	5.01e-05	CcSEcCtD
Tacrolimus—Asthenia—Epirubicin—prostate cancer	7.19e-06	4.91e-05	CcSEcCtD
Tacrolimus—Pruritus—Epirubicin—prostate cancer	7.09e-06	4.84e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Epirubicin—prostate cancer	6.85e-06	4.68e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Doxorubicin—prostate cancer	6.83e-06	4.67e-05	CcSEcCtD
Tacrolimus—Asthenia—Doxorubicin—prostate cancer	6.65e-06	4.54e-05	CcSEcCtD
Tacrolimus—Dizziness—Epirubicin—prostate cancer	6.62e-06	4.53e-05	CcSEcCtD
Tacrolimus—Pruritus—Doxorubicin—prostate cancer	6.56e-06	4.48e-05	CcSEcCtD
Tacrolimus—Vomiting—Epirubicin—prostate cancer	6.37e-06	4.35e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Doxorubicin—prostate cancer	6.34e-06	4.33e-05	CcSEcCtD
Tacrolimus—Rash—Epirubicin—prostate cancer	6.32e-06	4.32e-05	CcSEcCtD
Tacrolimus—Dermatitis—Epirubicin—prostate cancer	6.31e-06	4.31e-05	CcSEcCtD
Tacrolimus—Headache—Epirubicin—prostate cancer	6.28e-06	4.29e-05	CcSEcCtD
Tacrolimus—Dizziness—Doxorubicin—prostate cancer	6.13e-06	4.19e-05	CcSEcCtD
Tacrolimus—Nausea—Epirubicin—prostate cancer	5.95e-06	4.07e-05	CcSEcCtD
Tacrolimus—Vomiting—Doxorubicin—prostate cancer	5.89e-06	4.03e-05	CcSEcCtD
Tacrolimus—Rash—Doxorubicin—prostate cancer	5.84e-06	3.99e-05	CcSEcCtD
Tacrolimus—Dermatitis—Doxorubicin—prostate cancer	5.84e-06	3.99e-05	CcSEcCtD
Tacrolimus—Headache—Doxorubicin—prostate cancer	5.81e-06	3.97e-05	CcSEcCtD
Tacrolimus—Nausea—Doxorubicin—prostate cancer	5.51e-06	3.76e-05	CcSEcCtD
Tacrolimus—ABCB1—Metabolism—CYP17A1—prostate cancer	2.08e-06	2.35e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1B—prostate cancer	2.07e-06	2.35e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDKN1A—prostate cancer	2.07e-06	2.35e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTEN—prostate cancer	2.07e-06	2.34e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—prostate cancer	2.06e-06	2.33e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.06e-06	2.33e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TH—prostate cancer	2.05e-06	2.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—UCP3—prostate cancer	2.05e-06	2.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PDHA1—prostate cancer	2.05e-06	2.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTA3—prostate cancer	2.05e-06	2.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TCN2—prostate cancer	2.05e-06	2.32e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—prostate cancer	2.04e-06	2.32e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.04e-06	2.31e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP3A4—prostate cancer	2.03e-06	2.3e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—COMT—prostate cancer	2.03e-06	2.3e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	2.02e-06	2.29e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APC—prostate cancer	2.02e-06	2.28e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CG—prostate cancer	2.02e-06	2.28e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTP1—prostate cancer	2.02e-06	2.28e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP1B1—prostate cancer	2e-06	2.26e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGF—prostate cancer	1.99e-06	2.26e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IRS1—prostate cancer	1.99e-06	2.26e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ITPR1—prostate cancer	1.98e-06	2.25e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NCOA2—prostate cancer	1.98e-06	2.24e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—prostate cancer	1.97e-06	2.24e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EP300—prostate cancer	1.97e-06	2.23e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFB1—prostate cancer	1.97e-06	2.23e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—prostate cancer	1.96e-06	2.22e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HSD3B1—prostate cancer	1.96e-06	2.22e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC22A3—prostate cancer	1.96e-06	2.22e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CTNNB1—prostate cancer	1.96e-06	2.22e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—prostate cancer	1.95e-06	2.21e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GSK3B—prostate cancer	1.94e-06	2.19e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GGT1—prostate cancer	1.93e-06	2.19e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—prostate cancer	1.93e-06	2.19e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—SRC—prostate cancer	1.92e-06	2.17e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—prostate cancer	1.91e-06	2.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CDKN1A—prostate cancer	1.91e-06	2.17e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—INS—prostate cancer	1.91e-06	2.16e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTEN—prostate cancer	1.91e-06	2.16e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NCOA1—prostate cancer	1.9e-06	2.16e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CG—prostate cancer	1.9e-06	2.16e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC5A5—prostate cancer	1.89e-06	2.14e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP19A1—prostate cancer	1.88e-06	2.13e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTA4—prostate cancer	1.88e-06	2.13e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TBXAS1—prostate cancer	1.88e-06	2.13e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TYMS—prostate cancer	1.87e-06	2.12e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CREBBP—prostate cancer	1.87e-06	2.12e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTM1—prostate cancer	1.85e-06	2.1e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STAT3—prostate cancer	1.85e-06	2.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IGF1—prostate cancer	1.85e-06	2.09e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—EP300—prostate cancer	1.85e-06	2.09e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP2E1—prostate cancer	1.85e-06	2.09e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTA2—prostate cancer	1.83e-06	2.07e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NQO1—prostate cancer	1.82e-06	2.07e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—prostate cancer	1.82e-06	2.07e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—LPL—prostate cancer	1.82e-06	2.06e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EP300—prostate cancer	1.82e-06	2.06e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—RXRA—prostate cancer	1.81e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCG5—prostate cancer	1.81e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SULT1A1—prostate cancer	1.81e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—INS—prostate cancer	1.8e-06	2.04e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TH—prostate cancer	1.8e-06	2.04e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SRC—prostate cancer	1.79e-06	2.03e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAP2K1—prostate cancer	1.78e-06	2.02e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP3A4—prostate cancer	1.78e-06	2.02e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CD—prostate cancer	1.77e-06	2.01e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SRC—prostate cancer	1.77e-06	2e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CREBBP—prostate cancer	1.77e-06	2e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—prostate cancer	1.76e-06	2e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTA1—prostate cancer	1.76e-06	2e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.76e-06	2e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP1A1—prostate cancer	1.76e-06	1.99e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SERPINE1—prostate cancer	1.75e-06	1.99e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP1B1—prostate cancer	1.75e-06	1.98e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—prostate cancer	1.75e-06	1.98e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—COMT—prostate cancer	1.75e-06	1.98e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HSD3B2—prostate cancer	1.74e-06	1.98e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NAT2—prostate cancer	1.74e-06	1.98e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTO1—prostate cancer	1.74e-06	1.98e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ERCC2—prostate cancer	1.74e-06	1.97e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTP1—prostate cancer	1.74e-06	1.97e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ITPR1—prostate cancer	1.71e-06	1.94e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STAT3—prostate cancer	1.71e-06	1.93e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FGF2—prostate cancer	1.7e-06	1.92e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GGT1—prostate cancer	1.69e-06	1.92e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.68e-06	1.9e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—prostate cancer	1.68e-06	1.9e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CA—prostate cancer	1.68e-06	1.9e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOS3—prostate cancer	1.67e-06	1.9e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CD—prostate cancer	1.67e-06	1.9e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LRP2—prostate cancer	1.67e-06	1.89e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PLCB2—prostate cancer	1.67e-06	1.89e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP2C18—prostate cancer	1.67e-06	1.89e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NCOA1—prostate cancer	1.67e-06	1.89e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP19A1—prostate cancer	1.64e-06	1.86e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—P4HB—prostate cancer	1.64e-06	1.86e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—MTHFR—prostate cancer	1.64e-06	1.86e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—JAK2—prostate cancer	1.63e-06	1.84e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—prostate cancer	1.62e-06	1.84e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TYMS—prostate cancer	1.61e-06	1.83e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARA—prostate cancer	1.61e-06	1.82e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TGFB1—prostate cancer	1.6e-06	1.82e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTM1—prostate cancer	1.6e-06	1.81e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.6e-06	1.81e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MDM2—prostate cancer	1.59e-06	1.8e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—RXRA—prostate cancer	1.59e-06	1.8e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—prostate cancer	1.59e-06	1.8e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—prostate cancer	1.58e-06	1.8e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFB1—prostate cancer	1.58e-06	1.79e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—NOS3—prostate cancer	1.58e-06	1.79e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—LPL—prostate cancer	1.57e-06	1.77e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ERBB2—prostate cancer	1.57e-06	1.77e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.55e-06	1.76e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—prostate cancer	1.55e-06	1.76e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CB—prostate cancer	1.55e-06	1.75e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MED12—prostate cancer	1.53e-06	1.73e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—COMT—prostate cancer	1.53e-06	1.73e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTP1—prostate cancer	1.52e-06	1.72e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GNG5—prostate cancer	1.52e-06	1.72e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP1A1—prostate cancer	1.51e-06	1.71e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CAV1—prostate cancer	1.51e-06	1.71e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ERCC2—prostate cancer	1.5e-06	1.7e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ITPR1—prostate cancer	1.5e-06	1.7e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—prostate cancer	1.49e-06	1.68e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL8—prostate cancer	1.49e-06	1.68e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—prostate cancer	1.48e-06	1.68e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—prostate cancer	1.46e-06	1.66e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NCOA3—prostate cancer	1.46e-06	1.66e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CB—prostate cancer	1.46e-06	1.65e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CA—prostate cancer	1.46e-06	1.65e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1B—prostate cancer	1.45e-06	1.64e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—prostate cancer	1.45e-06	1.64e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CASP3—prostate cancer	1.42e-06	1.61e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—prostate cancer	1.42e-06	1.61e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TYMS—prostate cancer	1.41e-06	1.6e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—MTHFR—prostate cancer	1.41e-06	1.6e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTM1—prostate cancer	1.4e-06	1.58e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HPGDS—prostate cancer	1.39e-06	1.58e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.39e-06	1.57e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARA—prostate cancer	1.38e-06	1.57e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCND1—prostate cancer	1.38e-06	1.57e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CG—prostate cancer	1.38e-06	1.56e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—LPL—prostate cancer	1.37e-06	1.55e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CTNNB1—prostate cancer	1.37e-06	1.55e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—prostate cancer	1.37e-06	1.55e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CA—prostate cancer	1.37e-06	1.55e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ACHE—prostate cancer	1.35e-06	1.53e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTT1—prostate cancer	1.35e-06	1.53e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CA—prostate cancer	1.35e-06	1.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—prostate cancer	1.34e-06	1.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CDKN1A—prostate cancer	1.34e-06	1.52e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.34e-06	1.51e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTEN—prostate cancer	1.34e-06	1.51e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP1A1—prostate cancer	1.33e-06	1.5e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—prostate cancer	1.32e-06	1.5e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ERCC2—prostate cancer	1.31e-06	1.49e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—INS—prostate cancer	1.3e-06	1.48e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CAV1—prostate cancer	1.3e-06	1.47e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.3e-06	1.47e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PRKACB—prostate cancer	1.29e-06	1.47e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—prostate cancer	1.29e-06	1.46e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.28e-06	1.45e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CREBBP—prostate cancer	1.28e-06	1.45e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EP300—prostate cancer	1.27e-06	1.44e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTEN—prostate cancer	1.26e-06	1.43e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.24e-06	1.41e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SRC—prostate cancer	1.24e-06	1.4e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MTHFR—prostate cancer	1.24e-06	1.4e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NCOA2—prostate cancer	1.22e-06	1.38e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARA—prostate cancer	1.21e-06	1.37e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CD—prostate cancer	1.21e-06	1.37e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—prostate cancer	1.21e-06	1.37e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—EP300—prostate cancer	1.2e-06	1.36e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT3—prostate cancer	1.19e-06	1.35e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—prostate cancer	1.19e-06	1.35e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—prostate cancer	1.19e-06	1.35e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CG—prostate cancer	1.19e-06	1.34e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.16e-06	1.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NOS3—prostate cancer	1.14e-06	1.29e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CAV1—prostate cancer	1.14e-06	1.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.14e-06	1.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NQO1—prostate cancer	1.12e-06	1.27e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—INS—prostate cancer	1.12e-06	1.27e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—prostate cancer	1.12e-06	1.26e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—prostate cancer	1.11e-06	1.26e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TH—prostate cancer	1.11e-06	1.25e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFB1—prostate cancer	1.11e-06	1.25e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—prostate cancer	1.1e-06	1.24e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CREBBP—prostate cancer	1.1e-06	1.24e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—prostate cancer	1.09e-06	1.23e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.08e-06	1.22e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CB—prostate cancer	1.05e-06	1.19e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—prostate cancer	1.04e-06	1.18e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GGT1—prostate cancer	1.04e-06	1.18e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CD—prostate cancer	1.04e-06	1.18e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CG—prostate cancer	1.04e-06	1.18e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NCOA1—prostate cancer	1.03e-06	1.16e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—prostate cancer	1.03e-06	1.16e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.01e-06	1.15e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NOS3—prostate cancer	9.84e-07	1.11e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—INS—prostate cancer	9.83e-07	1.11e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—RXRA—prostate cancer	9.78e-07	1.11e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CREBBP—prostate cancer	9.63e-07	1.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CA—prostate cancer	9.42e-07	1.07e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—COMT—prostate cancer	9.42e-07	1.07e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTP1—prostate cancer	9.38e-07	1.06e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ITPR1—prostate cancer	9.23e-07	1.05e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CD—prostate cancer	9.13e-07	1.03e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—prostate cancer	9.11e-07	1.03e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTEN—prostate cancer	9.11e-07	1.03e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CB—prostate cancer	9.08e-07	1.03e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—prostate cancer	9e-07	1.02e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CA—prostate cancer	8.89e-07	1.01e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TYMS—prostate cancer	8.72e-07	9.87e-06	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—EP300—prostate cancer	8.69e-07	9.84e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NOS3—prostate cancer	8.62e-07	9.76e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTM1—prostate cancer	8.62e-07	9.76e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LPL—prostate cancer	8.46e-07	9.58e-06	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—prostate cancer	8.34e-07	9.45e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP1A1—prostate cancer	8.17e-07	9.25e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ERCC2—prostate cancer	8.1e-07	9.18e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CB—prostate cancer	7.96e-07	9.01e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—prostate cancer	7.88e-07	8.93e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTEN—prostate cancer	7.85e-07	8.89e-06	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—prostate cancer	7.7e-07	8.72e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MTHFR—prostate cancer	7.61e-07	8.63e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—EP300—prostate cancer	7.48e-07	8.48e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARA—prostate cancer	7.47e-07	8.46e-06	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—prostate cancer	7.26e-07	8.23e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CAV1—prostate cancer	7.02e-07	7.96e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTEN—prostate cancer	6.88e-07	7.79e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—EP300—prostate cancer	6.56e-07	7.43e-06	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CA—prostate cancer	6.43e-07	7.28e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CG—prostate cancer	6.4e-07	7.25e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—INS—prostate cancer	6.06e-07	6.86e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CREBBP—prostate cancer	5.93e-07	6.72e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CD—prostate cancer	5.62e-07	6.37e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CA—prostate cancer	5.54e-07	6.27e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NOS3—prostate cancer	5.31e-07	6.02e-06	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—prostate cancer	5.25e-07	5.95e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CB—prostate cancer	4.9e-07	5.55e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—prostate cancer	4.86e-07	5.5e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CA—prostate cancer	4.85e-07	5.49e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—prostate cancer	4.52e-07	5.12e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTEN—prostate cancer	4.24e-07	4.8e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—EP300—prostate cancer	4.04e-07	4.58e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—prostate cancer	3.96e-07	4.49e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.99e-07	3.39e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—prostate cancer	2.44e-07	2.77e-06	CbGpPWpGaD
